CrownBio Agrees to be Acquired by JSR of Japan in $400 Million Deal

Crown Bioscience, a CRO with facilities in China, Taiwan, the US and Europe, will be acquired for $400 million by JSR Corporation of Japan. The offer was a 105% premium to the previous day's CrownBio stock price. With an extensive library of patient-derived xenograft (PDX) models, CrownBio offers translational programs for drug discovery and development in oncology, inflammation, cardiovascular and metabolic disease research. JSR is known as a materials sciences company, primarily for rubber-type products. It has recently expanded into life science through acquisitions. More details.... Stock Symbol: (TPEX: 6554) Share this with colleagues: // //